Can HIV Be Eliminated? Understanding Current Treatments and Research

Scientific progress in HIV medicine has been remarkable. Today, people living with HIV in the United States can expect a near-normal life expectancy when they have consistent access to treatment. Yet the virus continues to affect hundreds of thousands of Americans, and the path toward a true cure remains complex. Understanding where things stand — from daily medications to cutting-edge research — offers a clearer picture of what is possible and what challenges remain.

HIV in America Today

According to the Centers for Disease Control and Prevention, approximately 1.2 million people in the United States are living with HIV. Around 13 percent of them are unaware of their status. New infections have declined significantly over the decades, but disparities persist — particularly among Black and Latino communities, gay and bisexual men, and people in the South. HIV in America today is no longer a universal death sentence, but it is far from evenly managed across all populations.

How Antiretroviral Therapy Works

Antiretroviral therapy, commonly referred to as ART, is the cornerstone of HIV treatment. It does not eliminate the virus from the body, but it works by suppressing viral replication to undetectable levels in the blood. When the viral load is undetectable, the immune system can recover and function more effectively, and crucially, the virus cannot be sexually transmitted to others — a concept known as Undetectable = Untransmittable, or U=U. Most modern ART regimens involve one tablet taken once daily, combining two or three antiretroviral drugs from different classes. These medications have become dramatically more tolerable compared to earlier generations of HIV treatment.

Long-Acting Shots and PrEP

One of the most significant recent advances in HIV treatment and prevention is the development of long-acting injectable options. Rather than taking a daily pill, patients can now receive injections every one to two months that maintain suppression of the virus. Cabotegravir and rilpivirine, administered together as intramuscular injections, became the first complete long-acting injectable regimen approved by the FDA for HIV treatment. On the prevention side, long-acting injectable cabotegravir has also been approved as a form of PrEP — pre-exposure prophylaxis — for people who are HIV-negative but at risk. Traditional oral PrEP, such as Truvada or Descovy, remains effective and widely used. These options represent a meaningful shift in how prevention and care can be delivered to people who may struggle with daily medication adherence.

The Search for an HIV Cure

Despite the success of ART, the search for an HIV cure is ongoing and increasingly focused. The main obstacle is the viral reservoir — dormant copies of HIV that hide inside resting immune cells and are invisible to both the immune system and current medications. Two primary strategies dominate current research: the shock-and-kill approach, which aims to reactivate hidden virus so the immune system can destroy infected cells, and the block-and-lock method, which seeks to permanently silence the reservoir instead. A small number of individuals — sometimes referred to as the Berlin Patient, the London Patient, and a few others — have been functionally cured after receiving bone marrow transplants from donors with a rare genetic mutation that confers HIV resistance. While not a scalable solution, these cases have provided critical scientific insight into what a cure might look like.

Barriers in Access and Equity

Even as treatments improve, barriers in access and equity continue to define the HIV landscape in the United States. Cost is a significant factor — brand-name antiretroviral drugs can cost tens of thousands of dollars annually without insurance coverage. The Ryan White HIV/AIDS Program provides federal funding to help uninsured and underinsured individuals access care, and generic versions of many medications have improved affordability. However, structural barriers including lack of health insurance, geographic isolation, stigma, and mistrust of the healthcare system continue to prevent many people from receiving timely diagnosis and consistent treatment. Addressing these disparities is widely considered as essential to ending the HIV epidemic as any medical breakthrough.

Progress in HIV treatment and research over the past four decades has been extraordinary by any measure. From ART that keeps the virus suppressed to injectable PrEP that removes the need for a daily pill, the tools available today are more effective and accessible than ever before. A complete cure has not yet been achieved, but the scientific understanding of how to pursue one has never been stronger. Whether elimination is measured in individual viral loads or national infection rates, the direction of progress is clear — even as the work ahead remains substantial.